Acro Biomedical (ACBM) Shares Outstanding (Weighted Average) (2015 - 2025)

Acro Biomedical has reported Shares Outstanding (Weighted Average) for 11 years, with the latest figure at $60.0 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) changed 0.0% year-over-year to $60.0 million; the trailing twelve-month figure through Dec 2025 stood at $60.0 million (changed 0.0% YoY), and the FY2025 full-year result was $60.0 million, changed 0.0% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $60.0 million, roughly flat from $60.0 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $60.0 million in Q4 2021, with the low at $47.8 million in Q1 2021.
• Average Shares Outstanding (Weighted Average) over 5 years is $59.3 million, with a median of $60.0 million recorded in 2021.
• Year-over-year, Shares Outstanding (Weighted Average) changed 0.0% in 2021 and gained 25.72% in 2022.
• Tracing ACBM's Shares Outstanding (Weighted Average) over 5 years: stood at $60.0 million in 2021, then changed by 0.0% to $60.0 million in 2022, then changed by 0.0% to $60.0 million in 2023, then changed by 0.0% to $60.0 million in 2024, then changed by 0.0% to $60.0 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $60.0 million (Q4 2025), $60.0 million (Q3 2025), and $60.0 million (Q2 2025), per Business Quant data.

Peer Comparison